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Abstract
Background: Low-grade extraskeletal osteosarcomas (ESOS) are extremely rare.
Case presentation: We present the first case of low-grade ESOS of the chest wall, which occurred in a 30-year-old
man. Because of initial misdiagnosis and patient’s refusal of surgery, the diagnosis was done after a 4-year history
of a slowly growing mass in soft tissues, leading to a huge (30-cm diameter) calcified mass locally extended over
the left chest wall. Final diagnosis was helped by molecular analysis of MDM2 and CDK4 oncogenes. Unfortunately,
at this time, no surgical treatment was possible due to loco-regional extension, and despite chemotherapy, the
patient died one year after diagnosis, five years after the first symptoms.
Conclusion: We describe the clinical, radiological and bio-pathological features of this unique case, and review the
literature concerning low-grade ESOS. Our case highlights the diagnostic difficulties for such very rare tumours and
the interest of molecular analysis in ambiguous cases.
Background
Osteosarcoma (OS) typically develops in the intramedul-
lary cavity of long bones of adolescents and young
adults and is a high-grade tumour [1,2]. Extraskeletal
osteosarcoma (ESOS) is a very rare form of OS (~5%)
located in the soft tissues without connection to the ske-
leton. Its usual aspect is that of a large and deep high-
grade bone-forming sarcoma, developed in the limbs of
patients older than 40 years [2,3], with a very aggressive
behaviour [4].
Low-grade ESOS, whose histology is similar to well-
differentiated intraosseous and parosteal OS, is extre-
mely rare. To date only six cases have been reported in
the literature. Here, we describe a new case of low-
grade ESOS, which developed in the chest wall. Initial
diagnosis, based on radiological and histological aspects,
was erroneously myositis ossificans. Correct final diag-
nosis, suspected by the clinical evolution, was confirmed
by molecular analysis, but was too late, and the patient
died from extensive loco-regional progression. We hope
that this case report underlines the diagnostic difficulties
of this tumour, and the interest of molecular analysis in
ambiguous cases.
Case presentation
The patient was a 30-year-old man, Caucasian type, with-
o u ta n ys p e c i f i cm e d i c a lp e r s o n a lo rf a m i l i a lh i s t o r y .H e
was referred to our institution in November 2006 for
diagnosis and treatment of a huge tumour of the left
chest wall, detected for the first time 4 years earlier.
Indeed, in May 2002, he presented a 3-cm painless,
mobile, intramuscular mass on the left shoulder near sca-
pula, three months after a benign trauma on this region.
Magnetic resonance imaging (MRI) showed elements in
favour of a myositis ossificans circumscripta. Percuta-
neous biopsy showed areas of osteogenesis with mature
bone trabeculae in muscle. The intertrabecular space
revealed benign-appearing fibroblastic proliferation. The
retained diagnosis was myositis ossificans. The benignity
of this disease with usual spontaneous stabilisation or
regression [5], and the lack of functional impact of the
lesion led the physicians to decide observation.
However, the patient was lost to follow-up, and the
mass continued to grow slowly during two years. A sec-
ond percutaneous biopsy was performed in May 2004.
Histological analysis showed an intramuscular tumour
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mature bone trabeculae (Figure 1). The morphological
features were quite similar to that of the first biopsy,
but with some worrisome features such as the absence
of classical “zonal phenomenon”, and more florid fusi-
form proliferation and bone forming. Because of the
long clinical history and the pathological aspect, the
diagnoses of “atypical” myositis ossificans or heterotopic
ossification were evoked and a surgical removal was
proposed. The patient refused, and consulted another
physician who prescribed diphosphonate treatment dur-
ing a few months.
The patient was then lost to follow-up during 17 months
until November 2006, when he was referred to our institu-
tion because the mass had kept growing, leading to a
shoulder immobilisation. The ECOG status was 1, and the
p a t i e n tp r e s e n t e daf r o z e nl e f ts h o u l d e ra s s o c i a t e dw i t h
ipsilateral radial and cubital paralysis and cervical pain.
Physical examination found a voluminous, plane, hard and
immobile mass extended from the basicervical region to
the scapulo-humeral joint an df r o mt h el e f ts i d eo ft h e
chest wall to the axillary region. Biologically, there was not
any abnormality except an elevation of serum alkaline
phosphatases. Radiological images were impressive. CT
scan showed a huge calcified heterogeneous mass, with
kystic and solid elements (Figure 2A). The mass had a
25-cm transversal diameter, an 18-cm antero-posterior
diameter and a 30-cm cranio-caudal diameter. It included
the left scapula, the periscapular muscles and the chest
wall, with intercostal invasion to the pleura and muscular
extension to the left arm (triceps). Tc99 bone scan showed
a large hyperfixation of the whole left side of the chest
(Figure 2B). PET-scan with 18-FDG showed the mass
localised in the chest left side, crossing the median line at
the first sternocostal joint. Hyperfixation was heteroge-
neous and moderate with a few highly metabolic zones. A
subcutaneous lesion was also observed in the right pec-
toral muscle (SUV max = 7 g/ml), as well as pleural
abnormalities.
The diagnosis of low-grade ESOS was strongly sus-
pected. For confirmation, the pathological samples
removed in May 2004 were collected for re-examination,
and notably for molecular analysis of MDM2 and CDK4
oncogenes, whose amplification had been reported in
low-grade intraosseous and parosteal osteosarcomas
[6-9]. As shown in Figure 3A-B, CDK4 displayed a strong
nuclear staining of fusiform cells by immunohistochemis-
try (IHC), whereas MDM2 had a more focal positivity.
Fluorescence in situ hybridization (FISH) analysis showed
high amplification for both MDM2 and CDK4 (Figure
3C), confirming the diagnosis of low-grade ESOS.
Unfortunately at this time, more than 4 years after the
first symptoms, curative surgical resection was not pos-
sible because of to the loco-regional extension. We
delivered chemotherapy with an API/AI sequential regi-
men, which combined adriamycin (A), cisplatinum (P)
and ifosfamide (I). The disease was stable after 2 API/AI
cycles. After 4 additional API cycles, the disease pro-
gressed with extension of cutaneous nodules and
tumour mass associated to the apparition of left pleuri-
tis. The ECOG status was 3, and the patient complained
of thoracic pain and dyspnoea. Palliative radiation ther-
apy was not possible technically due to the tumour
volume. A thoracoscopic talcage was done, followed by
trabectedin-based chemotherapy. Three weeks after the
first cycle, the patient deteriorated rapidly and died of
respiratory failure secondary to loco-regional extension,
5 years after the initial symptoms.
Discussion
L o w - g r a d eE S O Sa r ee x t r e m e l yr a r ew i t ho n l y6c a s e s
reported to date in the English literature since 1953
[10-14]. To our knowledge, the present case is the
seventh case reported, and the first one developed in
the chest wall.
These cases are summarised in Table 1. The sex ratio is
4 F/3 M, and the median age is 40 years. These tumours
likely arise from the sarcomatous transformation of
Figure 1 Microscopic features.( A) Proliferation of fusiform cells between muscle fibres (HES × 10). (B) Foci of osteogenesis with bland fusiform
cells and no mitosis (HES × 20).
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Evolution is slow, and the diagnosis is delayed with a
median interval after the discovery of the mass of 4 years
(range, 2 to 10 years). This delay explains the large size of
tumours at diagnosis (median 14 cm, ranging from 5 to
30 cm). However, high-grade histological features (dedif-
ferentiation and high mitotic activity) may appear after a
long period in analogy to what happens in low-grade
parosteal OS, thus leading to accelerated evolution, like
in our case with rapid loco-regional extension, or in two
cases with metastatic diffusion [10,14]. Early diagnosis of
this tumour is crucial to allow an adequate surgical resec-
tion, which represents the sole curative treatment, as
confirmed by the prolonged complete remissions
observed in the 4 out of 5 patients initially treated with
complete surgery.
Figure 2 Radiological features 4.5 years after the first symptoms.( A) CT scan: thoracic transversal view showing a voluminous
heterogeneous highly calcified mass. It included the whole left chest wall and the left scapula, with intercostal invasion to the apical pleura
(black arrows) and the antero-superior mediastinum (bolt) with trachea deflection to the right. (B) Bone scan with Technecium 99: see the
heterogeneous extended hyperfixation of the whole left side of the chest. There was a muscular extension to the triceps leading to a frozen
scapulo-humeral joint.
Figure 3 CDK4 and MDM2 analysis.( A) Immunohistochemistry with anti-CDK4 antibody showing strong and quite diffuse nuclear staining of
fusiform cells (× 20). (B) Immunohistochemistry with anti-MDM2 antibody showing a more focal nuclear positivity. (C) Fluorescence in situ
hybridization of one neoplasic cell: high nuclear amplification of CDK4 (red signals) and MDM2 (green signals), with more than 20 copies (× 40).
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early stages with other ossified lesions of soft tissues:
benign lesions such as myositis ossificans circumscripta
(MOC), ossifying lipoma, soft tissue osteoma or chon-
droma, and ossifying fibromyxoid tumour, as well as
malignant lesions such as classical high-grade ESOS, par-
osteal OS, mesenchymal chondrosarcoma, and synovial
sarcoma. MOC is a benign heterotopic ossification of soft
tissues characteristically associated with direct trauma
[15]. It is one of the most important differential diagnoses,
which was initially evoked - based on radiological and/or
pathological aspects - in at least 3 out of the 7 reported
cases of low-grade ESOS. Furthermore, a number of cases
of ESOS presumably arising from MOC have been
reported [16-19]. In MOC, both mature and immature
bone is seen, as well as a prominent spindle cell and chon-
droid component, with a specific architecture described as
the “zonal phenomenon”. This phenomenon refers to the
presence of a clearly benign, reactive rim of mature bone
at the periphery, which encompasses a central area of fusi-
form cells and immature bone interlaced with osteoid and
chondroid. In our patient, several initial aspects led physi-
cians to erroneously propose this diagnosis: i) the initial
traumatism a few weeks before the discovery of the
tumour, ii) the first MRI observation which showed an
extraosseous mass with a mature calcification peripherally
predominant, iii) and the pathological aspects of mature
lamellar bone synthesis by non atypical cells without
abnormal mitoses. However, the radiological modifications
observed later with the development of a centrifuge ossifi-
cation corresponding to microscopic features to a reverse
pattern of ossification (“reverse zonal phenomenon”), and
of course, the progressive tumour growth and extension
were that of a malignant tumour. Due to the initial
misdiagnosis followed by the absence of follow-up, and
the patient’s refusal of surgery, the correct diagnosis was
done too late and evolution was fatal.
Today, molecular analyses may resolve the diagnostic
dilemma between low-grade ESOS and benign lesions.
Amplification of genes in the 12q13-15 region, such as
SAS, CDK4 and MDM2, is relatively frequent in osteo-
sarcoma, notably in low-grade parosteal OS, making
them suitable as markers for distinguishing them from
benign ossifying [6-9]. In our patient, IHC and FISH
analyses for MDM2 and CDK4 were done on 2006 from
paraffin-embedded tumour samples biopsied on 2004.
They showed the overexpression and amplification of
these two oncogenes, thus ruling out the diagnosis of
myositis ossificans and confirming that of sarcoma. To
o u rk n o w l e d g e ,i ti st h ef i r s tc a s eo fl o w - g r a d eE S O S
with documented molecular alterations.
Conclusion
Our case is the seventh case of low-grade ESOS
reported in literature, and the first case located in the
chest wall. It highlights the importance and difficulty of
early diagnosis of this very rare tumour, which may be
confused with numerous benign diseases, notably myosi-
tis ossificans. Misdiagnosis may be fatal, as surgery is
the only curative approach for these patients. In this
context, it is worth noting the importance of molecular
analysis (amplification and/or ovexpression of MDM2
and CDK4) to help diagnosis in ambiguous cases.
Consent
Written informed consent was obtained from the
patient’s relatives for publication of this case report and
any accompanying images.
Table 1 Seven cases of low-grade ESOS reported in literature
Ref. Sex/
Age
Initial
diagnosis
Tumour location Largest
diameter
Treatment Clinical outcome
[10] M/44 Myositis
ossificans
Right thigh 5 cm S Lung metastases, 4 years, death
[11] F/57 Low-grade ESOS Right popliteal
fossa
24 cm S Disease-free,
5 years
[12] F/74 Parosteal OS Left axilla 14 cm S Disease-free,
2 years
[13] F/35 Myositis
ossificans
Left leg 11 cm S Disease-free,
4 years
[14] F/40 Parosteal OS Back, para-spinal 9 cm S Lost to follow-up,
2 months
[14] M/32 Low-grade ESOS Right thigh
and others
16 cm S + CT Lung and retroperitoneum metastases, 4 years, death
Our
case
M/30 Myositis
ossificans
Chest 30 cm CT Loco-regional extension,
death 5 years after first symptoms and 1 year after
diagnosis
M, male; F, female; ESOS, extraskeletal osteosarcoma; OS, osteosarcoma; S, surgery; CT, chemotherapy.
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